Bergles, D. E., & Richardson, W. D. (2016). Oligodendrocyte Development and Plasticity. Cold Spring Harbor Perspectives in Biology, 8, ... The Development of E-Commerce in Brazil: A Pre, During and ...

With a 2025 development camp right around the corner, a key Russian prospect is expected to make his way to Montreal. A fourth-round draft pick (110th overall) of the Canadiens in 2023, ...

ATAC-seq and Cut&Tag data demonstrate the prominent effect of Tcf4 loss on genes related to oligodendrocyte development, providing compelling evidence for Tcf4’s role in promoting opening and active ...

More than 80% of the chemicals had no effect on oligodendrocyte development. However, 292 were cytotoxic — killed the oligodendrocytes — and 47 inhibited oligodendrocyte generation.

Study: Pervasive environmental chemicals impair oligodendrocyte development.Image Credit: Lightspring / Shutterstock. Background . Human exposure to environmental chemicals, especially during the ...

The study, “ Deficiency in the omega-3 lysolipid transporter Mfsd2a leads to aberrant oligodendrocyte lineage development and hypomyelination,” was published in the Journal of Clinical ...

Researchers identified a special transporter protein, Mfsd2a, that plays a critical role in regulating the brain cells responsible for protecting nerves with myelin sheaths. Loss of myelin sheaths can ...

Deficiency in the omega-3 lysolipid transporter Mfsd2a leads to aberrant oligodendrocyte lineage development and hypomyelination. Journal of Clinical Investigation , 2023; DOI: 10.1172/JCI164118 ...

If oligodendrocyte-lineage cells use autocrine/paracrine mechanisms to promote development and myelination, one would predict that (1) blocking secretion from oligodendrocyte-lineage cells would ...

We found that recombinant L-PGDS protein rescued the PD:ibot oligodendrocyte development defect in vitro (Figure 9A, B, text page 27). Thanks to an excellent suggestion by Reviewer#1, we also added ...

OPC1 is an oligodendrocyte progenitor cell ... Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.